Invent a Better Everyday | Dubai, UAE | G42

Make Enquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hayat Biotech

As your partner in science and life, Hayat Biotech challenges the barriers of science to reimagine the future of life.

Hayat Biotech
Hayat Biotech Logo.png

Your Partner in Science + Life

A joint venture between Sinopharm CNBG and G42, based in ADGM, Abu Dhabi, UAE, Hayat Biotech is on a continuous journey to expand its diversified portfolio through innovative research & development endeavors with a desire to better humanity.

Visit Website

Solutions

01

Biologics

Strengthening patient well-being through primary preventive medicine that drives immunization and resistance.

02

Diagnostics

Improving medical accuracy through tailored treatments that increase efficiency and reliably differentiate diseases.

03

Treatment

Uncovering modern antibody and biotherapeutic solutions through innovative science-based technology.

04

Lifestyle

Redefining cosmetic procedures through enhanced high-quality medical aesthetic treatments.

Meet Our Team

Hongbing Cong

Chief Executive Officer

Naser Alyammahi

Deputy Chief Executive Officer

Dr. Nawal Al Kaabi
Item
Hongbing Cong

Chief Executive Officer

Hongbin is the CEO of Hayat Biotech and led the team that manufactured Hayat Vax, the first Covid-19 vaccine produced in the MENA region. Actively involved in phase III clinical trials of Sinopharm Covid-19 vaccines and instrumental in bringing tens of millions of Sinopharm vaccines into the UAE and region. Before this role, he was the vice chairman of Falcon Associates as a strategic adviser to Dubai leadership. He was a Partner at PricewaterhouseCoopers China and had almost 20 years of experience in providing corporate finance services. Hongbin has advised governments on infrastructure building and financing for roads and bridges, metro systems, and power and water treatment plants. Hongbin was a financial advisor to Beijing Olympic Games and provided financial advisory services to London Olympic Games, Sochi Winter Olympics and Rio Olympic Games.

Item
Naser Alyammahi

Deputy Chief Executive Officer

Naser has over 15 years of experience in the public and private sectors, specializing in corporate and competitive strategy, key partnerships and government affairs. Currently, Deputy CEO of Hayat Biotech, dedicated to the development of UAE’s capabilities in the field of biotechnology and life sciences, Naser was previously managing the strategic partnerships of the group and government and private sector relations at G42, and spearheading the Group’s business engagement strategy with government authorities and private sector. As a member of the various Steering Committees and Chairman of the Office Tendering Committee, Naser was also led the sourcing efforts and the negotiations of high-value procurement activities. He was also acting Executive Director and Director of Projects and strategic Studies at the UAE Ministry of State Office of H.E. Dr. Sultan Al Jaber, identifying cross-sectoral opportunities and development of policies and strategies.

Item
Dr. Nawal Al Kaabi

Nawal Al Kaabi, a senior advisor to Hayat Biotech, is a pediatric infectious diseases consultant at Sheikh Khalifa Medical City. She is the Chair of the SEHA infectious diseases and infection Control council. She was Chief Medical Officer in Sheikh Khalifa Medical City from Mar. 2017 to Jan. 2022 and the National Covid-19 Clinical Committee Chair since February 2020. She is the Principal Investigator of multiple clinical trials, including the randomized, double-blind, parallel placebo-controlled, phase III clinical trial to evaluate the safety and protective efficacy of inactivated SARS-CoV-2 vaccines.

Send an inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For better web experience, please use the website in portrait mode